Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.65 |
| ▸ | FBP1 | P09467 | 1/20 | 0.63 |
| ▸ | VCP | P55072 | 1/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.53 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3028232 | 1.00 | NFE2L2 (0.65) | NFE2L2FBP1VCPCYP19A1GAA | |
| SCHEMBL31609672 | 0.87 | NFE2L2 (0.61) | NFE2L2FBP1VCPCYP19A1GAA | |
| SCHEMBL30605279 | 0.87 | NFE2L2 (0.61) | NFE2L2FBP1VCPCYP19A1GAA | |
| SCHEMBL9629088 | 0.84 | ALDH1A1 (0.60) | NFE2L2FBP1VCPCYP19A1GAA | |
| SCHEMBL9629097 | 0.84 | ALDH1A1 (0.60) | NFE2L2FBP1VCPCYP19A1GAA | |
| SCHEMBL7137045 | 0.84 | NFE2L2 (0.61) | NFE2L2FBP1VCPCYP19A1GAA | |
| SCHEMBL15498134 | 0.84 | NFE2L2 (0.89) | NFE2L2FBP1VCPCYP19A1GAA | |
| SCHEMBL4632192 | 0.83 | NFE2L2 (0.65) | NFE2L2FBP1VCPCYP19A1GAA | |
| SCHEMBL6158116 | 0.83 | NFE2L2 (0.65) | NFE2L2FBP1VCPCYP19A1GAA | |
| SCHEMBL4632191 | 0.83 | NFE2L2 (0.65) | NFE2L2FBP1VCPCYP19A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2984055-B1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | MATERIA INC (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-3265458-A1 | BENZAZEPINE DICARBOXAMIDE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2018-01-10 | — | — | EP | disclosed |
| US-9758445-B2 | Preparation of surfactants via cross-metathesis | MATERIA, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9663459-B2 | Preparation of surfactants via cross-metathesis | MATERIA, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9562019-B2 | Substituted pyridazines as EGFR and/or KRAS inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-02-07 | — | — | US | disclosed |
| EP-2518063-B1 | Pyridazinones and furan-containing compounds | SLOAN-KETTERING INST FOR CANCER RES (US) | 2017-02-01 | — | — | EP | disclosed |
| WO-2016142250-A1 | BENZAZEPINE DICARBOXAMIDE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-15 | — | — | WO | disclosed |
| US-20160186094-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | MATERIA, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160145204-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | MATERIA, INC. | 2016-05-26 | — | — | US | disclosed |
| EP-2984055-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | Materia, Inc. (US) | 2016-02-17 | — | — | EP | disclosed |
| WO-2015126462-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | MATERIA, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| EP-2099770-B1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN KETTERING INST CANCER (US) | 2015-06-10 | — | — | EP | disclosed |
| WO-2014169080-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | MATERIA, INC. (US) | 2014-10-16 | — | — | WO | disclosed |
| US-20130131062-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DJABALLAH HAKIM (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2518063-A1 | Pyridazinones and furan-containing compounds | Sloan-Kettering Institute For Cancer Research (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20100210649-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-08-19 | — | — | US | disclosed |
| US-7169786-B2 | Isoxazoline derivatives as anti-depressants | JANSSEN-CILAG S.A. (ES) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131062-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DPYD, PDXK, TYMP | NFE2L2 1030/4885FBP1 123/4885VCP 4089/4885 |
| US-20160186094-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | SMURF2, EPHX2, SMURF1 | NFE2L2 1025/4885FBP1 2094/4885VCP 1432/4885 |
| US-20100210649-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DPYD, PDXK, TYMP | NFE2L2 1030/4885FBP1 123/4885VCP 4089/4885 |
| US-20160145204-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | SMURF2, SMURF1, ABCB4 | NFE2L2 1863/4885FBP1 2703/4885VCP 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.